Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Bodrogi

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Acta Medica Hungarica|January 1, 1994
Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumoursI Bodrogi, M Baki, J Horti, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 1, 1991
Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenograftsB Vincze, I Pályi, D Daubner, et al.
Spinal Cord|August 20, 2002
A PET study on the characterization of partially reversible radiogenic lower motor neurone diseaseO Esik, Z Lengyel, G Sáfrány, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2008
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)C Theodore, I Skoneczna, I Bodrogi, et al.
Pathology Oncology Research : POR|January 12, 2017
A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in HungaryZs Küronya, I Sinkovics, P Ágoston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)M Gershanovich, H A Chaudri, D Campos, et al.
Voprosy Onkologii|October 26, 1999
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]M Gershanovich, Kh Chaudri, D Campos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyS B Kaye, G M Mead, S Fossa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.
Breast Cancer Research and Treatment|November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelA Di Leo, S Chan, M Paesmans, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Acta Medica Hungarica|January 1, 1994
Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumoursI Bodrogi, M Baki, J Horti, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 1, 1991
Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenograftsB Vincze, I Pályi, D Daubner, et al.
Spinal Cord|August 20, 2002
A PET study on the characterization of partially reversible radiogenic lower motor neurone diseaseO Esik, Z Lengyel, G Sáfrány, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2008
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)C Theodore, I Skoneczna, I Bodrogi, et al.
Pathology Oncology Research : POR|January 12, 2017
A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in HungaryZs Küronya, I Sinkovics, P Ágoston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 1998
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)M Gershanovich, H A Chaudri, D Campos, et al.
Voprosy Onkologii|October 26, 1999
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]M Gershanovich, Kh Chaudri, D Campos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer studyS B Kaye, G M Mead, S Fossa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United KingdomS D Fosså, S B Kaye, G M Mead, et al.
Breast Cancer Research and Treatment|November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelA Di Leo, S Chan, M Paesmans, et al.
Pageof 7